Introduction {#sec1_1}
============

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder of hematopoietic cells caused by chromosomal abnormalities, specifically the Philadelphia chromosome t(9;22) \[[@B1]\]. Current Food and Drug Administration (FDA)-approved therapies include the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, dasatinib, and bosutinib \[[@B2]\]. Even with these therapies, approximately 20--30% of patients fail to have a complete cytogenetic response on first-line imatinib \[[@B2], [@B3]\]. Salvage therapy includes second- and third-generation TKIs, but there is a mixed response as they can be more selective depending on a variety of patient factors \[[@B2]\].

Bosutinib was primarily studied and evaluated for patients who had an inadequate response to imatinib \[[@B4]\]. Studies evaluating long-term use of bosutinib have shown 84% overall survival, with most adverse events happening within the first 2 years of therapy \[[@B5]\]. With third-generation TKIs, such as ponatinib, showing promising responses in patients with extensive prior treatment \[[@B6]\], it is difficult to draw the line between searching for complete cytogenic remission and the risk of continually changing therapies, particularly in elderly individuals. We discuss the treatment of an elderly woman who has had suboptimal responses to many first- and second-line therapies, currently on bosutinib for 5 years with relatively stable results.

Case Presentation {#sec1_2}
=================

We present a 75-year-old white female with refractory CML, diagnosed in 2004, who has gone through multiple BCR/ABL inhibitors, namely imatinib, nilotinib, and dasatinib, currently on bosutinib 300 mg daily for 5 years who has achieved hematological remission but has never achieved complete molecular response (CMR).

The patient was found to have elevated white blood cell (WBC) count in June of 2004. Subsequent bone marrow aspirate and biopsy were diagnostic for CML. Therapy was initiated with imatinib and was effective until 2007 when her WBC count started to rise again. She was then started on nilotinib 400 mg, to which she responded but again subsequently regressed, with her WBC count going from 13,500 to 40,000/mL. Dasatinib was started, which the patient did not tolerate, and was stopped after 1 month due to cardiac symptoms which the patient described as her heart feeling like it was going to "flop out." At this point in time, she was placed on interferon-α, but it was stopped due to side effects.

She was seen by our center in 2012 and had recently been placed back on imatinib 800 mg, which was subsequently lowered to 600 mg a day, as well as hydroxyurea. A bone marrow biopsy done in January of 2012 showed chronic-phase CML. Until then, no mutational analysis had been done to evaluate her drug resistance to TKIs. At this time, she also developed pericardial and pleural infusion, most likely from imatinib, and underwent a pericardial window placement in the same month.

Follow-up with mutational analysis was negative, and it was decided to retry dasatinib, as she had progressed through imatinib and nilotinib. Dasatinib 50 mg daily was started with close monitoring and plans to use pulse steroids and diuresis if fluid buildup should develop. She developed a cough relieved by steroids with no effusions present. In March 2013, she was tolerating dasatinib, and her dose was increased to 50/100 mg every other day. BCR/ABL PCR done at this time was 31.83%. BCR/ABL continued to be stable, but no decline in levels was noted. Bone marrow biopsy in May 2013 was negative for BCR/ABL, but the PCR was still concerning. It was decided to try a course of ponatinib at 15 mg daily. After initiation of therapy, she had a decrease in her platelet counts. She was switched to bosutinib in January 2014 due to ponatinib being taken off the market. After the switch to bosutinib, her BCR/ABL clones once again started to increase. A switch back to dasatinib was offered, but the patient was reluctant, and it was decided to continue on bosutinib.

At this point, it was decided not to monitor her BCR/ABL levels as she was not a transplant candidate. The focus was on hematological remission alone. Since that time, the patient\'s only major complaint with bosutinib has been some bouts of diarrhea, and even this has mainly been when dosage increase was attempted. BCR/ABL levels rose from 44% in 2015 to 65% in February of 2016. Kinase domain mutation analysis was negative again. BCR/ABL decreased from 65 to 52.3% in May 2016. At this time, her bosutinib was increased from 300 to 500 mg every day due to another rise in BCR/ABL. This elevated dose caused an increase in diarrhea, and it was dropped down to 300 mg as it was previously. Since that time in 2016, her BCR/ABL waxed and waned, but she continued in hematological remission. Currently, she is still on bosutinib 300 mg daily with plans to add interferon-α if disease progression is observed.

Discussion {#sec1_3}
==========

Treatment options for those with inadequate responses to frontline TKIs remain a substantial clinical problem in most patients. Although age has been shown to be an independent prognostic indicator, studies have not demonstrated any association of BCR/ABL mutations leading to TKI resistance \[[@B6]\]. In our patient, no BCR/ABL mutations have been shown, leading to further unknowns about her future clinical course. With limited availability of therapeutics after exhausting current options, treatment can become a burden on the provider and the patient.

In the case of our patient, mutational analysis has yielded no results to date. Specific therapies, such as the use of ponatinib for T315I kinase domain mutation \[[@B7]\], have been beneficial for a subset of patients who do not respond to initial first- and second-line therapies. There are other treatments currently in clinical trials which have yielded promising results for a slightly different mechanism of action from other TKIs \[[@B8]\]. Our case presents an interesting view of mutation-negative disease that still has not responded to many treatments. Ponatinib is a potential option that has not yet been explored, although it is against our patient\'s wishes to keep switching treatment regimens due to being relatively stable on current therapy. Research has been conducted to assess TKI discontinuation \[[@B9]\] but is limited in terms of continuation of current therapy despite lack of remission.

A further consideration is the choice between CMR versus major molecular response. Studies in Japan and France have shown that there is no harm in stopping therapy in patients with a major molecular response, and this may be just as effective, and cheaper, than waiting for a CMR \[[@B9]\]. There is emerging evidence that criteria for consideration of manageable levels of remission could be more lenient to allow for wider clinical judgment. While no studies have been conducted to assess the continuation of therapy despite CMR, we postulate that, when therapeutic exhaustion has occurred, remaining on a tolerable dose and monitoring BCR/ABL PCR levels is a clinically suitable option, especially given patient social factors, such as age and unwillingness to change therapies.

Although CMR is the goal in the treatment of CML, this goal must be assessed in the setting of the patient\'s preferences and after assessing how the patient responds to the therapeutic regimen. CML patients who have evidence of CMR still have evidence of leukemic disease on PCR even after imatinib discontinuation \[[@B10]\]. So, in this light, it could be argued that patients with CML are never fully cured as we might proclaim; rather, we have merely attached this label to certain patient populations. We surmise evidence from our patient falls in line with what John Goldman stated in his 2006 paper, if a therapy can prevent recurrence and resistance, you can provide an "operational cure" \[[@B11]\].
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